BYSI
BeyondSpring, Inc.
0.88
USD
This page is just a preview of the data found in TrendSpider’s full version
BeyondSpring, Inc. stock is down -15.52% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 November’s closed higher than October.
Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.
